È­ÀåÇ° ¼ººÐ ¿¬±¸

ÇÏÀ̵å·Ï½ÃÇdzªÄݷз¹Æ¼³ë¿¡ÀÌÆ®(hydroxypinacoloneretinoate)

±Û¾´ÀÌ : ¿À¶óŬ1         ÃÖÃÊÀÔ·ÂÀÏ : 2020-11-08         ÃÖÁ¾¼öÁ¤ÀÏ : 2020-11-08         Á¶È¸¼ö : 453

1 ¿ä¾à¼³¸í ÇÏÀ̵å·Ï½ÃÇdzªÄݷз¹Æ¼³ë¿¡Æ®´Â
Æ®·¹Æ¼³ëÀÎ(½ºÆ¼¹Ù, alltransretinoic acid)ÀÇ ¿¡½ºÅ׸£ÀÌ´Ù.
Æ®·¹Æ¼³ëÀÎ(½ºÆ¼¹Ù)º¸´Ù ÀÚ±ØÀÌ Àû°í
Äݶó°Õ»ý¼ºÀº À¯»çÇÏ´Ù.
·¹Æ¼³¯(·¹Æ¾¾Ëµ¥ÇÏÀ̵å)À̳ª ·¹Æ¼³îº¸´Ù Äݶó°Õ»ý¼º ³ô´Ù.



2 INCI
3 ÇѱÛÀü¼ººÐ¸í
4 µ¿ÀǾî
5 ¹°¸®È­ÇÐÀû Ư¡ È­ÇнÄ
±¸Á¶½Ä
ºÐÀÚ·®
½Ç¿ÂÇü»ó
²ú´ÂÁ¡
³ì´ÂÁ¡
¿ë¸Å
6 ¿ø·á Á¤º¸ ¿ø·á °ø±Þ»ç
kg´ç °¡°Ý
ÁÖ»ç¿ë ³óµµ
100g Á¦Ç°´ç ¼ººÐ°¡°Ý
7 »ý»ê ¹æ½Ä
8 ¼ººÐ¿¡ ´ëÇÑ ¿ª»ç
9 È¿´É °æ±¸º¹¿ëÈ¿´É
±¹¼ÒµµÆ÷ È¿´É Antiaging effects of retinoid hydroxypinacolone retinoate on skin models

jaad.2018.05





Tretinoin, also known as all-trans retinoic acid (ATRA), is well known for its antiaging effects on skin. However, skin irritation, photochemical instability, and concerns about toxicity have hindered the use of ATRA in cosmetic products. Typically, milder retinoid derivatives are used, which must first be metabolized to more active forms by several enzymatic steps in the skin, which reduces their potency. Therefore, it is desirable to find new molecules that have increased retinoic acid–like activity without the negative side-effects. Hydroxypinacolone retinoate (HPR), a cosmetic grade ester of ATRA, is unique in that it processes innate retinoic acid activity, binding directly with retinoid receptors without the need for metabolic breakdown to more biologically active forms. It has been demonstrated to be more stable and cause less skin irritation than retinol. Here, we compared levels of gene transcription by HPR, ATRA, retinol (Rol), retinaldehyde (Ral), and retinyl palmitate (RP) by evaluating binding of the retinoic acid receptor to retinoid acid responsive elements (RARE) in DNA using a RARE reporter assay. In addition, we compared the antiaging properties of HPR to ATRA by testing the effects on collagen levels and skin irritation in organotypic skin models. Skin models were treated for 5 days with three doses of HPR and ATRA; vehicle controls skins were treated with vehicle alone. Basal media was collected for procollagen and 1L-1¥á ELISA analysis. On day 5, skins were fixed, paraffin embedded, sectioned, and stained with Masson trichrome (for collagen). RARE assay results showed that HPR had greater levels of gene transcription than Rol, Ral, and RP at the same concentrations, and was less cytotoxic to cells at a 10 times higher concentration; however, HPR did not achieve gene transcription levels of ATRA. Procollagen ELISA results showed that skins treated with HPR significantly increased procollagen production compared with untreated control skins, and was similar to ATRA. Qualitative assessment of collagen levels from histologic staining of skins corroborated these results, with the highest dose of HPR out-performing ATRA. IL-1¥á ELISA analysis showed that HPR did not induce more (or less) inflammatory response than either ATRA or the vehicle control. Together these data suggest that HPR is an effective alternative to ATRA and other less potent retinoids in the treatment of aging skin without the detrimental side-effects.



Ãâó) https://www.jaad.org/article/S0190-9622(18)31012-0/abstract

10 È­ÀåÇ°³» ±â´É
ÁÖ±â´É¡Ü
ºÎ±â´É¡Û
¿ëÁ¦
°è¸éÈ°¼ºÁ¦
¹ß¸²¼ºÁ¦
Á¡ÁõÁ¦
pHÁ¶ÀýÁ¦
ų·¹ÀÌÆÃÁ¦
Çâ
¹æºÎÁ¦
È¿´É¼ººÐ µî¡Ü
11 È¿´É¼ººÐ
(DOSPAW-O)
ÁÖÈ¿´É¡Ü
ºÎÈ¿´É¡Û
DRY
º¸½ÀÁ¦
À庮°³¼±Á¦
ÇÔ½ÀÁ¦
¹ÐÆóÁ¦
OILY
Ç׿ÀÀÏÁ¦
ÇÇÁöºÐºñ ¾ïÁ¦Á¦ (5a-reductase inhibitor ¾ïÁ¦Á¦)
ÇÇÁöºÐºñ ¾ïÁ¦Á¦ (ÇÇÁö¼± ¼¼Æ÷ »ç¸êÁ¦)¡Ü
ÇÇÁöÈíÂøÁ¦
°¢ÁúÁ¦°ÅÁ¦ ¡Ü
SENSITIVE
Ç׿°Á¦
NFkB ¾ïÁ¦Á¦ ¡Ü
phospholipase ¾ïÁ¦Á¦
Cycloxygenase ¾ïÁ¦Á¦
À庮°³¼±Á¦
PIGMENT
»ö¼Ò¾ïÁ¦Á¦
tyrosinase ¾ïÁ¦Á¦
¸á¶ó´Ñ À̵¿ ¾ïÁ¦Á¦
°¢ÁúÁ¦°ÅÁ¦
ACNE
¿©µå¸§¾ïÁ¦Á¦
ÇÇÁöºÐºñ ¾ïÁ¦Á¦ (5a-reductase inhibitor ¾ïÁ¦Á¦)
ÇÇÁöºÐºñ ¾ïÁ¦Á¦ (ÇÇÁö¼± ¼¼Æ÷ »ç¸êÁ¦) ¡Ü
°¢ÁúÁ¦°ÅÁ¦¡Ü
Ç×±ÕÁ¦(MIC) ¡Ü
Ç׿°Á¦¡Ü
WRINKLE
ÁÖ¸§¾ïÁ¦Á¦
(Ç¥ÇÇ)
Ç¥ÇǼ¼Æ÷Áõ½ÄÁ¦ ¡Ü
Ç¥ÇǼ¼Æ÷ºÐÈ­Á¦
À庮±â´É°³¼±Á¦
WRINKLE
ÁÖ¸§¾ïÁ¦Á¦
(ÁøÇÇ)
¼¶À¯¾Æ¼¼Æ÷Áõ½ÄÁ¦
Äݶó°Õ¼¶À¯»ý¼ºÁ¦ ¡Ü
ź·Â¼¶À¯»ý¼ºÁ¦ ¡Ü
GAGs»ý¼ºÁõ°¡Á¦ ¡Ü
Äݶó°Õ¼¶À¯ºÐÇØ°¨¼ÒÁ¦ ¡Ü
OXIDANT
Ç×»êÈ­Á¦
Ç×»êÈ­Á¦ ¡Ü
12 ¿ÏÁ¦Ç° Á¤º¸ ÁÖ¿ä ÇÔÀ¯ Á¦Ç°
´ÚÅÍ¿À¶óŬ Á¦Ç°
13 °á·Ð ÇÏÀ̵å·Ï½ÃÇdzªÄݷз¹Æ¼³ë¿¡ÀÌÆ®´Â ·¹Æ¼³î¼ººÐÀ̳ª ·¹Æ¼³¯¼ººÐº¸´Ù ÀÚ±ØÀºÀû°í Äݶó°ÕÀç»ýÈ¿°ú°¡ ³ô¾Æ ÇâÈÄ ·¹Æ¼³ëÀ̵å È­ÀåÇ°ÀÇ ´ë¾ÈÀ¸·Î ÁÖ¸ñ¹ÞÀ» °ÍÀ¸·Î º»´Ù.
14 Àοë³í¹®Ãâó) https://www.jaad.org/article/S0190-9622(18)31012-0/abstract